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improve graft quality in freshly grafted ovaries?
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Abstract
Background: A major concern in ovarian transplants is substantial follicle loss during the initial period of hypoxia.
Adipose tissue-derived stem cells (ASCs) have been employed to improve angiogenesis when injected into ischemic
tissue. This study evaluated the safety and efficacy of adipose tissue-derived stem cells (ASCs) therapy in the freshly
grafted ovaries 30 days after injection.
Methods: Rat ASCs (rASCs) obtained from transgenic rats expressing green fluorescent protein (GFP)-(5 × 104 cells/ovary)
were injected in topic (intact) or freshly grafted ovaries of 30 twelve-week-old adult female Wistar rats. The whole ovary
was grafted in the retroperitoneum without vascular anastomosis, immediately after oophorectomy. Vaginal smears were
performed daily to assess the resumption of the estrous cycle. Estradiol levels, grafts morphology and follicular viability
and density were analyzed. Immunohistochemistry assays were conducted to identify and quantify rASC-GFP+, VEGF
tissue expression, apoptosis (cleaved caspase-3 and TUNEL), and cell proliferation (Ki-67). Quantitative gene expression
(qPCR) for VEGF-A, Bcl2, EGF and TGF-β1 was evaluated using RT-PCR and a double labeling immunofluorescence assay
for GFP and Von Willebrand Factor (VWF) was performed.
Results: Grafted ovaries treated with rASC-GFP+ exhibited earlier resumption of the estrous phase (p < 0.05), increased
VEGF-A expression (11-fold in grafted ovaries and 5-fold in topic ovaries vs. control) and an increased number of blood
vessels (p < 0.05) in ovarian tissue without leading to apoptosis or cellular proliferation (p > 0.05). Estradiol levels were
similar among groups (p > 0.05). rASC-GFP+ were observed in similar quantities in the topic and grafted ovaries (p > 0.05),
and double-labeling for GFP and vWF was observed in both injected groups.
Conclusion: rASC therapy in autologous freshly ovarian grafts could be feasible and safe, induces earlier resumption of
the estrous phase and enhances blood vessels in rats. This pilot study may be useful in the future for new researches on
frozen-thawed ovarian tissue.
Keywords: Ovarian transplantation, Fertility preservation, Cellular therapy, Stem cells, Ovary
Background
Fertility preservation in patients who will undergo cyto-
toxic treatments is a matter of concern during thera-
peutic planning, and it is one of the foremost challenges
of the next decade [1–4]. The most recent option for
fertility preservation is the transplant of ovarian tissue,
which has led to antral follicle development and live
births [5–9].
Currently, more than 35 children born worldwide for
whom this technique was used [5, 7, 8, 10], and the most
attractive feature is the availability of thousands of oocytes
in tissue strips, which enables prompt retrieval and
fertilization [8–11]. Despite these successful outcomes,
ovarian transplantation is still considered an experimental
technique. The greatest concern is the short-term graft
survival as a result of substantial follicle loss during trans-
plantation [8, 9, 12].
Avascular ovarian grafts revascularize within 5 days
after transplantation [13–15]. Numerous studies in ani-
mals and humans have previously demonstrated that the
initial period of hypoxia is a determinant of the lifespan
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of the graft, and it is strongly negatively correlated with
the success of ovarian transplants [13, 16–18]. There-
fore, enhanced angiogenesis during this critical period
could minimize ischemic effects, which is the main
cause of follicular loss and ovarian injury. Several experi-
mental models developed for this purpose have demon-
strated promising results [19–26]. Specifically, cellular
therapy has been shown to preserve hypoxic tissues,
such as post infarction cardiac tissue. Important experi-
mental findings in recent years suggest a considerable
therapeutic potential for cellular replacement in the con-
text of acute myocardial infarction and chronic, progres-
sive cardiac disease [27–29].
Adipose tissue-derived stem cells (ASCs) have been
employed in order to contribute to angiogenesis because
these cells differentiate into or behave as endothelial
cells after injection into ischemic tissue [30–32]. How-
ever, the mechanism of the beneficial effect is uncertain.
ASCs exhibit a basal production of VEGF, which can be
influenced by hypoxia [33]. The beneficial effects of ASC
therapy on ischemic tissue may be mediated, at least in
part, by paracrine factors [34]. However, the effects of
cellular therapy on ovaries remain unclear.
ASCs enhance ovarian function when injected in rats
with chemotherapy-damaged ovaries [35–37]. Though, lit-
tle information is available regarding the therapeutic poten-
tial of an ovarian transplant. The aim of this study was to
evaluate the effect of rat ASCs (rASCs) injected into topic
or transplanted rat ovaries on regarding the safety and
effects on fresh graft function. This may be the first step to
evaluate cellular therapy on the ovarian tissue, for ensuring
that these cells may not change ovary morphology.
Methods
The study was performed at Laboratório de Ginecologia
Estrutural e Molecular (LIM-58), Disciplina de Ginecologia,
Departamento de Obstetrícia e Ginecologia, Hospital das
Clínicas da Faculdade de Medicina da Universidade de São
Paulo. (FMUSP), in cooperation with the Laboratory of
Genetics and Molecular Cardiology/Heart Institute (Incor)/
FMUSP. The Institutional Ethics Committee approved the
experimental procedures, which followed the institutional
guidelines for the care and use of laboratory animals
(protocol 190/10).
The study sample consisted of 30 twelve-week-old
adult female Wistar (Rattus norvegicus albinus) rats. The
animals had access to a breed-specific food formula and
water ad libitum throughout the experiment and were
maintained under adequate sanitary, lighting (12/12 h),
and temperature conditions in the animal laboratory.
Experimental design
Vehicle or rASCs obtained from the inguinal region of
Wistar rats transgenic for green fluorescent protein (GFP+)
were injected into 24 Wistar rats. The rats were distrib-
uted in four experimental groups (Fig. 1): 1) Topic
ovary + vehicle, 2) Topic ovary + rASC-GFP+, 3) Ovar-
ian graft + vehicle, and 4) Ovarian graft + rASC-GFP+. A
topic ovary is an intact ovary in which only a vehicle or
rASCs injection was performed. An ovarian graft is the
whole ovary grafted into the retroperitoneum without
vascular anastomosis, immediately after oophorectomy.
Collagen solution type I from rat tail (SIGM-C3867,
Sigma-Aldrich, Inc.), 3 mg/ml, pH = 7.2, was used as the
vehicle because previous studies have shown that the bene-
ficial effects of ASCs could be enhanced by co-injection
with biopolymers [28, 29]. An extra group (n = 6) was in-
cluded to compare the morphology of topic ovary with no
treatment or treated with vehicle in the same animal.
Cell isolation and ex vivo expansion
Inguinal subcutaneous adipose tissue was collected under
sterile conditions from 10-week-old male Wistar rats and
rinsed with phosphate-buffered saline (PBS). rASCs were
isolated, characterized, and maintained in culture as previ-
ously described [29]. The cells were used for experimental
procedures until passage 3. Details are available in the
Aditional file 1 (ASCs isolation and ex vivo expansion).
The morphological and replicative characteristics as
well as the immunophenotype (CD90+, CD29+, CD44+,
CD73+, CD31−, CD45−) of the ASCs have been previ-
ously described in our laboratory [38]. Although the
characterization has been performed extensively in
mouse adipose-derived stem cells (mASCs), our group
conducted some immunophenotyping assays in the rat
adipose-derived stem cells (rASCs). The percentage of
CD90- and CD29-positive cells, the primary markers of
a variety of various adult stem cells, was found to be
approximatelly 90 % (92.65 and 98.89 %, respectively)
in rASCs at the third culture passage (unpublished data
from Nakamuta et al.).
Vaginal smear collection
Vaginal smears were obtained daily pre-operatively from
each rat between 8:00 a.m. and 10:00 a.m. Only the
animals that exhibited at least two consecutive normal
four-day vaginal estrous cycles were included in the ex-
periment. Ovarian transplantation was performed during
the diestrus phase. Beginning on day 4 postoperatively
(PO), vaginal smears were performed daily until euthan-
asia, which was performed between days 30 and day 35,
always when the rats were in the diestrous phase.
Vaginal smears were obtained with a swab soaked in
physiological solution, placed on a standard slide and im-
mediately fixed in absolute alcohol for staining using the
Shorr-Harris technique. The smears were analyzed under
a light microscope at 10× and 40× magnification [39].
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Ovarian transplantation and cellular therapy
The animals were anesthetized with an intraperitoneal
injection of xylazine and ketamine at doses of 15 and
60 mg.kg−1 of body weight, respectively. The abdomino-
pelvic cavity was opened, and the ovaries were identified.
The ovarian pedicles were clamped and immediately li-
gated with 4–0 nylon suture. The fallopian tubes were
resected with periovarian adipose tissue fragments.
Each animal in the transplanted groups (n = 12) re-
ceived both autologous ovary transplants. Intact whole
ovaries were implanted in the retroperitoneum in the
proximity aorta and vena cava using a simple stitch of
4–0 nylon suture, without vascular anastomosis, each on
one side of the psoas muscle.
At this point, the transplanted groups were distributed
in according to the treatment, as follows (n = 6 for each
group): vehicle (25 μl of collagen solution/ovary) or
rASC-GFP+ (at a concentration of 5 × 104 cells in 25 μl
of vehicle/ovary). The technical standardization of ASCs
injection was performed according to a pilot project in
which we tested different vehicle volumes for cell deliv-
ery (ranging from 2 to 50 μl) using a surgical microscope
(16×). The standard dose of 25 μl was the lowest in
which no leakage was visually observed following the
injection, without changes in ovary morphology and ASC-
GFP+ were easily identified and quantified in ovarian
stroma (data not shown). The cells were injected by a sin-
gle shot into the center of the ovarian parenchyma in both
grafts. In the topic groups (n = 12), the only procedure per-
formed was the injection of vehicle or rASC-GFP+.
After the treatments, the wall closure was performed
using a 5–0 nylon monofilament thread on two planes, in-
cluding the peritoneum-aponeurotic muscle and the skin.
Graft retrieval and histological preparation
The animals underwent a second surgical procedure be-
tween PO days 30 and 35, always in the diestrus phase.
The abdominal cavity was opened, and the ovaries were
macroscopically identified and assessed. The muscle bed
was also assessed for vascularization and surrounding
adhesions. The grafts were subsequently removed whole.
Blood samples were collected from vena cava for serum
estradiol levels assay.
One ovarian graft was immediately fixed in 4 % parafor-
maldehyde for at least 24 h. Following fixation, the ovaries
were dehydrated, paraffin-embedded, serially sectioned at
5 μm, and mounted on glass microscope slides. Routine
hematoxylin and eosin (HE) staining was performed for
TOPIC OVARY (n=12)
INJECTION OF
Vehicle* (n=6) rASCs-GFP+ ** (n=6)
GRAFT OVARY (n=12)
BILATERAL OOPHORECTOMY
BILATERAL OVARIAN 
AUTOLOGOUS 
TRANSPLANTATION
INJECTION OF
GRAFT+VEHICLE GRAFT+rASCs-GFP+
LAPAROTOMY
TOPIC+VEHICLE TOPIC+rASCs-GFP
+
Vehicle* (n=6) rASCs-GFP+ ** (n=6)
Fig. 1 Experimental design
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histological examination with light microscopy. The ovar-
ian cortex was sectioned into two pieces of equal size, and
five representative sections were selected. The other graft
was placed in liquid nitrogen at −196 °C until real-time
polymerase chain reaction (RT-PCR) was performed. Fol-
lowing this procedure, the animals were euthanized with a
lethal dose of the previously used anesthetics.
Serum estradiol levels assay
Blood samples were collected from the vena cava, then
transferred to tubes and stored overnight at 4 °C. These
samples were centrifuged at 4 °C, 5000 rpm in a Sorvall
ST16R centrifuge with rotor model 75003629 (Thermo
Scientific, Asheville, NC, United States) for 15 min to sep-
arate the solid components from the serum, which was
stored at − 20 °C. Serum estradiol levels were assessed
using ELISA kits (Ucsn Life Sciences Inc., Wuhan, Hubei,
China) following the instructions of the manufacturer. Re-
sults are expressed in picogram per ml (pg/ml).
Morphological and morphometric analyses
Morphological evaluation was achieved through descrip-
tive analyses of the grafts. The assessment of follicular
quality was based on the cell density, the presence or ab-
sence of pyknotic bodies, and the integrity of the basement
membrane and oocyte. The follicles were classified as nor-
mal or degenerated according to these criteria, and only
the former were characterized and quantified [40, 41].
Viable follicles were classified into three groups: imma-
ture follicles (including primordial, primary and preantral),
antral and corpus lutem [40, 41]. Primordial follicle exhib-
ited only an oocyte and a layer of squamous cells. Primary
follicle exhibited an oocyte and one or more layers of cu-
boidal or prismatic cells but no antrum. Preantral follicle
exhibited an oocyte and not an antrum. Mature follicles
contained an oocyte with antrum. The corpus luteum ex-
hibited intact luteal cells that contained a nucleus and cells
surrounded by capillary blood vessels [18, 41–44]. To avoid
counting the same follicle more than once, only individual
follicles having an oocyte containing a nucleus were evalu-
ated. Counting was performed in eight fields per section.
The quantification of blood vessels (number/mm2) was also
performed using a computerized images system to obtain
and analyze eight fields per animal of HE stained ovarian
tissue (400×). All images of sections were obtained using
an image acquisition software system (Leica DM2500;
LEICA, Wetzlar, Germany). Two independent investigators
blinded to the experimental treatments performed all ana-
lyses under a microscope (LEICA).
Immunofluorescence and immunohistochemistry assays
Immunohistochemistry assays were performed for the
identification and quantification of rASC-GFP+ in the
ovarian stroma, and double-labeling immunofluorescence
was performed for GFP+ and the von Willebrand factor
(vWF), which is a marker of endothelial cells [45], to as-
sess the endothelial phenotype from injected rASC-GFP+.
Cross-sections embedded in paraffin were treated with
antigenic exposure and blocked with 2 % casein in PBS.
The tissue sections were incubated with anti-GFP anti-
body (1:500, ab6556, Abcam Inc., Cambrigde, MA, USA)
overnight at 4 °C for the identification and counting of
rASC-GFP+. The sections were incubated with a biotinyl-
ated rabbit secondary antibody (universal polymer anti-
mouse and rabbit Histofine® 1:400, Vector Laboratories,
Burlingame, CA, USA) and streptavidin peroxidase
followed by the peroxidase substrate diaminobenzidine
tetrahydrochloride according to the manufacturer’s in-
structions. Negative control slides were incubated with
normal rabbit serum and the secondary antibody alone.
For dual-fluorescence immunostaining, the cross-sections
were preincubated with 2 % casein in PBS followed by
anti-GFP antibody (1:50, ab6556, Abcam Inc., Cambrigde,
MA, USA) and anti-von Willebrand factor (1:50, ab6994,
Abcam Inc., Cambrigde, MA, USA) overnight at 4 °C. The
sections were subsequently incubated for 90 min with the
secondary antibody anti-rabbit Alexa fluor® 488 (1:200,
Life Technologies), anti-mouse Alexa fluor® 555 (1:200,
Life Technologies) and 4’,6-diamidino-2-phenylindole
(DAPI) (D3571, 1:100, Invitrogen, Life Technologies) to
identify cell nuclei. The number of rASC-GFP+/vWF+ in
which green fluorescence for GFP colocalized with red
fluorescence for vWF and blue fluorescence for DAPI
were counted from eight randomly selected microscopic
fields for each tissue section under a 200× objective. The
total tissue sections from six animals in each group were
used to measure the final cell number.
Measurement of angiogenesis, proliferation and
apoptosis
Sections that contained mature ovarian follicles were
immunostained to measure angiogenesis using tissue
VEGF expression (SANT-SC-152, 1:100, Santa Cruz
Biotechnology), proliferation using Ki67 expression
(Anti-human monoclonal antibody mib-1 m7240, 1:100,
Dako), and apoptosis using cleaved-caspase-3 expres-
sion (SANT-SC-1226, 1:100, Santa Cruz Biotechnology,
Inc. Santa Cruz, CA, EUA) and the terminal deoxynu-
cleotidyl transferase (TdT)–mediated dUTP nick-end
labeling (TUNEL) assay. The ovarian sections were pre-
pared as previously described and counterstained with
hematoxylin. The tissue slices for the TUNEL assay
were stained using a commercially available kit (In Situ
Cell Death Detection Kit, Fluorescein, Roche, Berlin,
Germany, 11684795910) following the manufacturer’s
instructions. The primary antibody was omitted for the
negative controls in each different immunohistochemis-
try staining.
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Images of the sections were obtained using an image
acquisition software system (Leica DM2500), and mea-
surements were made using Leica QWin V3 software. A
positive cell staining assessment was performed in eight
different fields per animal at 200× magnification and the
results are expressed as a percentage of the positive area
(arbitrary unity/mm2). A red-brown coloring of the cyto-
plasm/nucleus of the granulosa cells was specified as
positive staining (otherwise as negative staining). Two
independent investigators blinded to the experimental
treatments performed all measurements.
Quantitative PCR
Total RNA was extracted from topic or grafted ovaries
using the QIAzol Lysis Reagent and the RNeasy Micro
Kit (Qiagen, Hilden, Germany) according to the manu-
facturer's instructions. The solution was treated with the
RNase-Free DNase Set (Qiagen, Hilden, Germany). The
total RNA obtained from each sample was quantified
spectrophotometrically (ND100 NanoDrop®-Thermo
Fisher Scientific Inc. Co.), and the RNA integrity was
assessed by electrophoresis on a 1 % agarose gel.
Total RNA (1 μg) purified from each sample was tran-
scribed into cDNA via reverse transcription using the
RT2 First Strand Kit (Qiagen, Hilden, Germany) accord-
ing to the manufacturer’s instructions. The synthesized
cDNA underwent reaction in qPCR in PCR array plates
(RT2 Profiler PCR Arrays, cat. PARN-404Z, QIAGEN-
SABiosciences Corporation, USA) and the 7500 Real-
Time PCR System (Applied Biosystems, CA, USA) were
used. VEGFA (Catalog# PPR06748C; NM031836), Tgfβ
(Catalog# PPR06430B; NM021578), Bcl2 (Catalog#
PPR06577B; NM016993), and Egf (Catalog# PPR43509B;
NM012842) were analyzed. The qPCR results were calcu-
lated using the ΔΔCT method and specific SABiosciences
software. The gene expression results are provided as fold
changes, relative to the reference group (Topic + vehicle).
The software assign for this group (Topic + vehicle) a
value of 1, due to ΔΔCT relative expression analyses
method [46]. So, none value of fold expression lower than
1 might be considered significant. To enhance the bio-
logical significance of the gene expression, we stablished a
cut off of values >3 and <3. Genes with fold regulation >3
were considered upregulated and those with values <3
were considered downregulated. The values were obtained
for statistical analyzes, but relative expression reflects the
number of times that a specific gene was expressed com-
paring to a reference sample or group and a significant
value was considered to be a three-fold change in relative
to Topic + vehicle group. All gene expression levels were
normalized using the average of the housekeeping genes
(Actb, B2m, Hprt1, Ldha, and Rplp1) following the soft-
ware manufacturer’s instructions. Data were analyzed
using Web Basis Data Analysis at http://www.sabioscien-
ces.com/pcr/arrayanalysis.php.
Statistical analysis
According to the Shapiro-Wilk normality test, unpaired
t-test (for normal distribution) or Mann–Whitney tests
(for non-normal distribution) were utilized to compare
treatment groups (Topic + vehicle vs. Topic + rASC-
GFP+ and Graft + vehicle vs. Graft + rASC-GFP+). Topic
groups were compared with each other and the same
was done for transplanted groups. The results were
expressed as the mean ± standard deviation of the mean
(unpaired t-test) or median (Mann-Whitney tests). All
statistical analyses were performed using Graphpad
Prism 5.0 (Graphpad Software Inc, CA, USA). P values
lower than 0.05 were considered significant.
Results
rASC therapy does not interfere with ovarian
morphology, follicular pool or tissue viability
The non-absorbable stitch helped to identify the ovarian
grafts during euthanasia, and 100 % of the grafts were
recovered. The grafts were enwrapped in adipose tissue,
and some grafts exhibited a surrounding neovasculariza-
tion network, which was visible to the naked eye.
Morphologically, there were no difference in ovaries
with no treatment or treated with vehicle (extra group).
Ovarian follicles in both groups of topic ovaries at several
maturation stages (primordial, primary, preantral and an-
tral) were observed, and countless corpora lutea, most
whole but some degenerated, were also observed. There
was no difference with respect to treatment (rASC-GFP+
or vehicle) (Fig. 2).
A smaller concentration of ovarian follicles, corpora
lutea, interstitial cells, and ovarian stroma was observed in
both groups of transplanted ovaries in addition to the sur-
rounding fibrosis and inflammatory infiltrate. However,
there were ovarian follicles at several maturation stages and
the whole corpora lutea. Overall, the rASC-GFP+ did not
interfere with the ovarian morphology in either group
(Fig. 2). There were no significant differences in the number
of immature (topic p = 0.3168; graft p = 0.2386) and antral
follicles (topic p = 0.1823; graft p = 0.6652) with rASC-GFP+
however a reduction in corpora lutea in the grafted group
was observed (topic p = 0.2498; graft p = 0.0411) (Table 1;
Fig. 2a–c).
rASC therapy induces an earlier resumption of the
estrous phase in the transplanted group
All animals resumed cycling after transplantation, and
the transplanted animals treated with rASC-GFP+ ex-
hibited an earlier resumption of the estrous phase
compared with the respective controls (Topic + ve-
hicle: 7.1 ± 2.1 days vs. Topic + rASC-GFP+: 6 ± 1 days,
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p = 0.2615; Graft + vehicle: 11.6 ± 1.5 days vs. Graft +
rASC-GFP+: 9.2 ± 1.9 days, p = 0.0475). The rats in the
topic groups exhibited regular estrous cycles of four to
five days, but the rats in the grafted groups exhibited
significantly decreased numbers of estrous cycles with
increased durations of the diestrus phase.
rASC therapy does not interfere with estradiol levels both
in topic and grafted ovaries
Serum estradiol levels 30 days after treatment were
similar both in topic (Topic + vehicle: 6.43 ± 3.5 pg/ml
vs. Topic + rASC-GFP+: 8.1 ± 3.4 pg/ml) and grafted
(Graft + vehicle: 6.55 ± 2.27 pg/ml vs. Graft + rASC-
GFP+: 8.2 ± 5.05 pg/ml) groups (p > 0.05).
A
C
B
D E
Fig. 2 Representative photomicrographs of topic or freshly grafted ovarian tissue submitted to treatment with rASC-GFP+ or vehicle. HE Scale bar
500 μm. Zoom indicates area where blood vessels were counted (Scale bar 50 μm). Fo = Follicles. CL = Corpora Lutea. Fi = Fibrosis. Bottom figures
depict ovarian follicle density (mean) of immature follicles (a), antral follicles (b) and corpora lutea (c) (Data shown in mean ± SD in a and c and
median-interquartile range in b. #p = 0.0411. Unpaired t test) and blood vessel count (number/area) in Topic (2D) and Graft ovaries (2E) (*p = 0.0106.
**p = 0.0019. Unpaired t test)
Table 1 Ovarian follicles density according to treatment with
adipose tissue-derived stem cells from transgenic rats for green
fluorescent protein (rASC-GFP+), in topic and autologous grafted
ovary
Topic Graft
Vehicle rASC-GFP Vehicle rASC-GFP
Immaturea 18.2 ± 7.2 13.8 ± 5.6 10.6 ± 6 6.2 ± 2.6
Antralb 2.5(2.0–3.0) 3.0(2.8–3.5) 0.0(0.0–1.5) 0.0(0.0–1.0)
Corpora luteaa 4.0 ± 1.2 6.7 ± 4.7 6.7 ± 2.1 3.4 ± 1.5*
Topic vehicle vs. Topic rASC-GFP+; Graft Vehicle vs. Graft rASC-GFP+. *p= 0.0411 vs.
Vehicle. Data were shown in mean ± SD for Student t-test (a) or median-interquartile
range for Mann-Whitney sum test (b), in according to the Shapiro-Wilk
normality test
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rASC therapy promotes an increase in VEGF gene
expression and vessels in topic and grafted ovaries
The rASC-GFP+ injection significantly increased VEGF-A
gene expression in both injected groups (Topic + rASC-
GFP+ and Graft + rASC-GFP+ were 5- and 11-fold higher,
compared with Topic + vehicle) (Fig. 3) and these groups
had a greater number of blood vessels compared with their
respective controls (Topic + vehicle and Graft + vehicle)
(Fig. 2d–e). However VEGF labeling was increased only in
topic ovaries (Topic + rASC-GFP+) in the immunohisto-
chemistry assay (Table 2, Fig. 4).
On the other hand, the rASC-GFP+ injection didn’t in-
crease the expression of genes involved in cellular prolif-
eration (EGF and TGFβ1) and apoptosis (Bcl2) (Fig. 3).
In agreement with these findings, apoptosis (TUNEL
and caspase-3) and proliferation (ki67) rates in the im-
munohistochemistry assay were also similar between the
groups (p > 0.05) (Table 2, Fig. 4).
rASC-GFP+, identified by immunohistochemistry,
were observed only in the ovarian stroma, and a similar
number of cells in both injected groups were observed
(Topic + rASC-GFP+: 176.5 ± 85.4 vs. Graft + rASC-
GFP+: 147 ± 65.8, p = 0.6041) (Fig. 5a–b). Interestingly,
double immunostaining for GFP and vWF demon-
strated a colocalization of the two markers in some
clusters of ASCs in Topic + rASC-GFP+and Graft +
rASC-GFP+. vWF is a marker of the endothelial pheno-
type, and these data suggest that a fraction of the
rASCs could behave as endothelial cells (Fig. 5d–e).
Discussion
Our results demonstrated that cell therapy with rASC in
fresh ovarian grafts was safe and effective as evidenced
by the morphological and immunohistochemical param-
eters. The results also indicated an early resumption of
estrous cycle.
We chose in situ injection of rASC-GFP+ because pre-
vious studies have shown a massive cell loss following
intravenous injections [37]. No deformity, tumor forma-
tion, or atrophy was observed in the rASC-GFP+ rats, in-
dicating that the injection had no side effects. The
number of cells used in the literature has widely varied
[36–38]. One group with normal (topic) ovaries and an-
other group with grafted ovaries were used in the
current study because all previous studies in rats used
chemotherapy-induced ovarian damage. We used a con-
centration of 5 × 104 cells/ovary (1 × 105 cells/animal),
which was the lowest concentration used in previous
studies [36].
rASC-GFP+ were only found in the ovarian stroma, not
in follicular cells, which was described by other investiga-
tors in experimental models of chemotherapy-induced
ovarian lesion [35, 36]. However, the reason for this lim-
ited localization is unknown. A higher vascularization of
the stroma may, in part, explain this finding. The morpho-
logical results of the rASC-GFP+ group did not exhibit
atypical or irregular cells. This finding suggests that this
therapy is safe. Cell injections did not produce changes in
ovarian morphology at either site. Group differences, such
as a smaller number of ovarian follicles and the presence
of fibrosis, were observed, but adaptive mechanisms inher-
ent in the transplantation process [17, 18, 43, 44] were
likely the reason, not effects from the treatment (i.e., the
injection of rASC-GFP+). Therefore, the treatment can be
considered to be effective and stable in fresh ovarian tis-
sue, which differs from what has been previously observed
in the heart, in which very few cells remained at the injec-
tion site [28, 29, 34]. In this study, rASC-GFP+ settle in
the ovarian tissue after direct injection (Topic + rASC-
GFP+and Graft + rASC-GFP+). The groups exhibited simi-
lar morphology, and the evidence indicates that rASC-
GFP+ remain active in the ovarian stroma (both topic and
F
ol
d 
C
ha
ng
e 
re
la
te
d 
to
 G
1 
(T
op
ic
+
ve
hi
cl
e)
Topic+rASC-GFP+ Graft+vehicle Graft+rASC-GFP+
0
2
4
6
8
10
12
Bcl2
Egf
Tgfb
VEGFA
--------------------------------
Fig. 3 Gene expression of topic or grafted ovarian tissue submitted to treatment with rASC-GFP+ or vehicle, evaluated using qPCR. Each bar represents
the value of fold change compared with the control group (Topic + vehicle). A significant value was considered over a three-fold change (dashed line).
Data analyzed using Web Basis Data Analysis at http://www.sabiosciences.com/pcr/arrayanalysis.php
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grafted) to promote the expression of pro-angiogenic fac-
tors, such as VEGF and vWF.
The previously described finding does not strongly sup-
port the idea that engrafted cells differentiate into func-
tional vascular cells (transdifferentiation) or stem cells that
fuse with other local cells. The mechanisms involved in
stem cell-based therapy are not well understood. Engrafted
stem cells can produce encouraging paracrine signals for
cell survival in the ischemic environment [27, 45], and the
hypoxic microenvironment of the ovarian tissue may in-
fluence this type of action mechanism. Our finding dem-
onstrated that this therapy was associated with an early
functional resumption of the grafts, as demonstrated by
vaginal smear cytology. Further studies are needed to bet-
ter assess cells that express the endothelial phenotype be-
cause of the influence of a hypoxic environment. On
euthanasia day (30 days after operative procedures),
serum estradiol levels were similar in both groups
(topic or grafted) despite the treatment with rASC-GFP.
We didn’t colleted the blooda samples in the first days
after operative procedures. It may be a limitation to in-
terpret these data. As in animals treated with RASC-
GFP+ exhibited early functional return of the estrous
cycle, estradiol serial measurements could determine
the endocrine profile of this graft.
Human ASCs secrete a variety of growth factors [34];
however, we focused on VEGF, which is known to affect
follicular growth in ovaries and is stimulated under con-
ditions of hypoxia [34], similar to the conditions present
following transplantation. In our study, VEGF-A gene
expression was more pronounced in both groups treated
with rASC-GFP+, which may have led to an increase in
the number of blood vessels compared with the controls.
Fo
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Fig. 4 Photomicrographs of immunohistochemistry analysis for VEGF, Ki-67, Caspase-3 and TUNEL in ovarian follicles according to treatment with
rat adipose tissue derived stem cells transgenic for green fluorescent protein (rASC-GFP+) or vehicle, in topic or freshly grafted ovary. A red-brown
coloring of the cytoplasm/nucleus of the cells was specified as positive staining. For the negative controls, the primary antibody was omitted in each
different immunohistochemistry staining. Treatment with rASC-GFP+ enhanced VEGF expression in topic ovarian tissue. Scale bar 50 μm. Fo = Follicles.
VEGF = Vascular endothelial grown factor. TUNEL = terminal deoxynucleotidyl transferase (TdT)–mediated dUTP nick-end
Table 2 Immunohistochemistry analysis in ovarian follicles for
angiogenesis (VEGF), cellular proliferation (Ki-67) and apoptosis
(cleaved-caspase-3 and TUNEL), according to treatment with
Adipose Tissue-Derived Stem Cells from transgenic rats for
Green Fluorescent Protein (rASC-GFP), in topic and autologous
grafted ovary
Topic Graft
Vehicle rASC-GFP Vehicle rASC-GFP
VEGF 13.58 ± 4.4 27.13 ± 11.1* 25.46 ± 9.4 41.9 ± 11.7
Ki67 2.46 ± 0.55 2.12 ± 0.7 2.44 ± 1.5 1.72 ± 0.38
Caspase-3 4.23 ± 2.5 6.39 ± 2.9 6.97 ± 5.6 6.18 ± 3.44
TUNEL 0.03 ± 0.03 0.04 ± 0.08 0.13 ± 0.12 0.04 ± 0.05
Data are shown as percentage of positively stained follicle cells per area
(arbitrary unity/mm2). VEGF Vascular Endothelial Grown Factor, TUNEL Terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end
Data were shown in mean ± SD; Student t-test; *p = 0.0352 vs. Vehicle
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However, VEGF tissue expression was enhanced only in
the topic ovary treated with rASC-GFP+, a finding that
might be related to the late evaluated period after the
transplant (30 days).
Another interesting finding was the apparent equilib-
rium between proliferation and apoptosis in the tissue.
There was no increase in apoptosis- or proliferation-
related gene expression (Bcl2, Tgfb, and EGF), which
was also confirmed by immunohistochemistry. rASC-
GFP+, most likely through the release of cytokines, pre-
vented apoptosis (according to cleaved-caspase-3 and
TUNEL) in both groups; however, Bcl2 expression did
not change. These data support the previous evidence
indicating that rASC-GFP+ show beneficial effects, such
as the inhibition of apoptosis [47], inflammation [48],
and other immune responses [49] and the ability to pro-
duce angiogenic factors under hypoxia [50, 51].
In our study, the density of primordial and primary
follicles was significantly higher in the non-grafted
compared with grafted samples. These results clearly
demonstrated that ovarian tissue transplantation led to
follicle loss in agreement with the literature reports
[17, 18, 43, 44].
In addition, rASC-GFP treatment reduced the number
of corpora lutea in grafted ovaries; however, this finding
may not be a result of rASC-GFP+ injection. Corpora
lutea are not a useful indicator of ovarian activity be-
cause they can persist for up to 14 days. Thus three or
more generations of corpora lutea could exists from the
preceding ovulatory cycles [52].
Conclusion
The present study suggested that: 1) rASC-GFP+ therapy
does not interfere with ovarian morphology, follicular pool
or tissue viability; 2) rASC-GFP+ remain viable and in simi-
lar amounts in both topic and grafted ovaries and have an
endothelial-like phenotype (as indicated by double immu-
nostaining for GFP and vWF); 3) rASC-GFP+ therapy pro-
motes an increase in VEGF-A gene expression and the
number of blood vessels in ovarian tissue; and 4) rASC-
GFP+ therapy induced earlier functional resumption in
grafted ovaries, as indicated by estrous vaginal smears. This
pilot study may be useful in the future for new researches
on frozen-thawed ovarian tissue.
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